These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30539417)

  • 1. Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria.
    Pugh SJ; Fletcher MA; Charos A; Imekraz L; Wasserman M; Farkouh R
    Infect Dis Ther; 2019 Mar; 8(1):63-74. PubMed ID: 30539417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.
    Huang L; McDade CL; Perdrizet JE; Wilson MR; Warren SA; Nzenze S; Sewdas R
    Infect Dis Ther; 2023 Mar; 12(3):933-950. PubMed ID: 36774428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India.
    Ghia CJ; Horn EK; Rambhad G; Perdrizet J; Chitale R; Wasserman MD
    Infect Dis Ther; 2021 Dec; 10(4):2271-2288. PubMed ID: 34313958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.
    Perdrizet J; Horn EK; Nua W; Perez-Peralta J; Nailes J; Santos J; Ong-Lim A
    Infect Dis Ther; 2021 Dec; 10(4):2625-2642. PubMed ID: 34591259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy.
    Ansaldi F; Pugh S; Amicizia D; Di Virgilio R; Trucchi C; Orsi A; Zollo A; Icardi G
    Pathogens; 2020 Jan; 9(2):. PubMed ID: 31979079
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada.
    Wilson M; Wasserman M; Jadavi T; Postma M; Breton MC; Peloquin F; Earnshaw S; McDade C; Sings H; Farkouh R
    Infect Dis Ther; 2018 Sep; 7(3):353-371. PubMed ID: 29934878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.
    Strutton DR; Farkouh RA; Earnshaw SR; Hwang S; Theidel U; Kontodimas S; Klok R; Papanicolaou S
    J Infect; 2012 Jan; 64(1):54-67. PubMed ID: 22085813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
    Perdrizet J; Santana CFS; Senna T; Alexandre RF; Sini de Almeida R; Spinardi J; Wasserman M
    Hum Vaccin Immunother; 2021 Apr; 17(4):1162-1172. PubMed ID: 32966176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.
    Kim HY; Park SB; Kang ES; Lee SM; Kim HJ; Wasserman M
    Hum Vaccin Immunother; 2021 Mar; 17(3):909-918. PubMed ID: 32783576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
    Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
    Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
    Kuhlmann A; von der Schulenburg JG
    Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia.
    Perdrizet J; Lai YS; Williams S; Struwig VA; Wasserman M
    Infect Dis Ther; 2021 Mar; 10(1):507-520. PubMed ID: 33575966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia.
    Ordóñez JE; Orozco JJ
    Cost Eff Resour Alloc; 2015; 13():6. PubMed ID: 25878563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
    Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
    Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong.
    Lee KKC; Chia Wu DB; Topachevskyi O; Delgleize E; DeAntonio R
    Value Health Reg Issues; 2013 May; 2(1):64-74. PubMed ID: 29702855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.